SHAMAN PRODUCTS POISED TO PREVENT MULTIPLE FORMS OF CANCER.Shaman Pharmaceuticals, Inc. (OTCBB OTCBB
See OTC Bulletin Board (OTCBB). :SHPH), San Francisco, has announced that its standardized botanical extract, SP49400, which is being formulated into the Syn X Bar and other Shaman products, is poised to help prevent not just colorectal cancer, but multiple forms of other cancers by lowering insulin levels through weight loss.
Pre-clinical studies have shown SP49400 to be an effective treatment to help obese mice lose weight. There is also an expanding body of evidence showing that multiple forms of cancer, including breast cancer, kidney cancer and colorectal cancer, among a potential list of others, are diseases that are associated with obesity and the high insulin levels of Syndrome X. The new evidence points to treating Syndrome X as a way to reduce risk of these kinds of cancers.
We have known for some time that obesity increases the risk of cancer. We know that obesity worsens insulin resistance and produces high insulin levels. We know that half of all individuals with high insulin levels have high blood pressure. We know that high insulin levels lead to heart attack and polycystic ovary syndrome Polycystic Ovary Syndrome Definition
Polycystic ovary syndrome (PCOS) is a condition characterized by the accumulation of numerous cysts (fluid-filled sacs) on the ovaries associated with high male hormone levels, chronic anovulation (absent ovulation), . We also know that Syndrome X, when the pancreas is exhausted from secreting extra insulin, develops into type 2 diabetes type 2 diabetes
See diabetes mellitus. . Now multiple studies indicate that there may be a direct link between obesity, high insulin levels and cancer. The studies also show that high insulin levels may speed up the progression of cancer.
Rudolf Kaaks, Ph.D. and colleagues of the International Agency for Research on Cancer The International Agency for Research on Cancer (IARC, or CIRC in its French acronym) is an intergovernmental agency forming part of the World Health Organisation of the United Nations.
Its main offices are in Lyon, France. , Lyon, France, in an article published in the Journal of the National Cancer Institute (Vol. 92, No. 19, October 4, 2000), presented strong evidence linking colorectal cancer with high insulin levels. In this study of 14,275 subjects, Kaaks and associates, using C-peptide as a marker to measure insulin secretion, showed that the higher the baseline C-peptide, the greater was the increase in risk of colorectal cancer in individuals with the highest insulin levels.
Dr. P.J. Goodwin and colleagues of the Samuel Lunenfeld Research Institute The Samuel Lunenfeld Research Institute of Mount Sinai Hospital (Toronto), Ontario, Canada was established in 1985 by an endowment from the Lunenfeld and Kunin families. It comprises 31 principal investigators, has a budget of C$90 million (2005/6), has 225 trainees and over 550 at Mound Sinai Hospital, University of Toronto Research at the University of Toronto has been responsible for the world's first electronic heart pacemaker, artificial larynx, single-lung transplant, nerve transplant, artificial pancreas, chemical laser, G-suit, the first practical electron microscope, the first cloning of T-cells, , completed a study examining the connection between obesity, high insulin levels and breast cancer. The study, published in ASCO ASCO American Society of Clinical Oncology
ASCO Association of Schools and Colleges of Optometry (since 1941; Rockville, Maryland)
ASCO Australian Standard Classification of Occupations
ASCO Automatic Switch Company , Volume 19 2000, concluded that high insulin levels and obesity predicted breast cancer and risk of survival.
Wong-Ho Chow, Ph.D. and colleagues from the National Cancer Institute, have completed a study published in the New England Journal of Medicine The New England Journal of Medicine (New Engl J Med or NEJM) is an English-language peer-reviewed medical journal published by the Massachusetts Medical Society. It is one of the most popular and widely-read peer-reviewed general medical journals in the world. , Volume 343, Number 18. The study followed 363,992 Swedish men until death or the end of 1995. The men with kidney cancer were identified and the link between obesity, hypertension and risk of kidney cancer was studied. The results showed that the heavier individuals were, the greater their chances of developing kidney cancer. The study also indicated that high blood pressure, common to Syndrome X, predicted increased risk of kidney cancer. Reduction in blood pressure lowered the risk.
"A convincing body of evidence is being built," said Gerald Reaven, M.D., Professor Active Emeritus at Stanford University and Shaman Senior Vice President of Clinical Affairs, "that shows that efforts to maintain insulin sensitivity and low insulin levels might well be helpful in lowering risk of certain kinds of cancer. No intervention studies have been done yet to show that lowering insulin levels reduces the threat of cancer. However, until those results are available it seems sensible to keep our insulin levels as low as possible."
Syndrome X was first described in 1988 by Dr. Reaven, author of Syndrome X, The Silent Killer That Can Give You A Heart Attack, (Simon & Schuster Simon & Schuster
U.S. publishing company. It was founded in 1924 by Richard L. Simon (1899–1960) and M. Lincoln Schuster (1897–1970), whose initial project, the original crossword-puzzle book, was a best-seller. ). Shaman has developed its new Syn X Bar which is the company's first Syndrome X product on the market, in a line of dietary supplements originally formulated to mitigate the major risk factors for coronary heart disease coronary heart disease: see coronary artery disease.
coronary heart disease
or ischemic heart disease
Progressive reduction of blood supply to the heart muscle due to narrowing or blocking of a coronary artery (see atherosclerosis). and other disease manifestations. The Syn X Bar contains the careful balance of 15% protein, 40% fat (mostly monounsaturated monounsaturated /mono·un·sat·u·rat·ed/ (mon?o-un-sach´er-at?ed) of a chemical compound, containing one double or triple bond.
adj. ), and 45% carbohydrate. This ratio has been clinically proven to help maintain healthy insulin levels. Dr. Reaven's diet also helps people maintain healthy LDL cholesterol, a risk factor for coronary heart disease that is not associates with Syndrome X.
SP49400, which will be incorporated into the Syn X Bar and other products, comes from a West African tree. Traditional healers have used the stembark of this safe and natural product to treat a variety of disorders including obesity, fatigue, and type 2 diabetes. It is free of phenylpropanoline (PPA PPA 1. Palpation, Percussion & Ausculation 2. Pittsburgh pneumonia agent 3. Postpartum amenorrhea 4. Price per accession 5. Pure pulmonary atresia ) which the Food and Drug Administration has announced it would seek to remove from the market. SP49400 is also free of any form of ephedrine ephedrine (ĭfĕd`rĭn, ĕf`ĭdrēn'), drug derived from plants of the genus Ephedra (see Pinophyta), most commonly used to prevent mild or moderate attacks of bronchial asthma. or caffeine and in pre-clinical studies has demonstrated statistically significant weight loss with no change in level of food consumption.
Shaman has retained Roth Capital Inc., an investment bank that focuses on emerging growth and middle market companies, to provide a broad range of corporate finance, research, syndicate sales and trading services to assist Shaman in exploring strategic business opportunities to drive shareholder value. One of the assets Roth Capital will work with, among many others, is the Syn X line of products for lowering triglyceride levels, weight loss and promoting general cardiovascular health.
For more information about Syndrome X, what it is and who has it, visit http://www.syndromexweb.com.
Shaman Pharmaceuticals, Inc. is a leader in medicinal plant research and commercialization of proprietary dietary supplements. Shaman works collaboratively with indigenous communities to discover, harvest and reforest re·for·est
tr.v. re·for·est·ed, re·for·est·ing, re·for·ests
To replant (an area) with forest cover.
re medicinal plants. The company also provides cultural educational programs in conjunction with rainforest communities.
For more information, call 650/952-7070, ext. 466.